The purpose of this study is to compare the change of global cognitive performance after 52
weeks of intervention among participants with nonvalvular atrial fibrillation (NVAF)
receiving rivaroxaban versus a vitamin K antagonist (warfarin).
The secondary objectives are to compare, among participants with NVFA receiving rivaroxaban
versus warfarin :
- the changes of global cognitive performance after 26 weeks of intervention
- the changes of executive functions after 26 and 52 weeks of intervention
- the changes of episodic memory after 26 and 52 weeks of intervention
- the volumetric changes of the brain after 26 and 52 weeks of intervention
- the changes of independence and autonomy after 26 and 52 weeks of intervention
- the changes of serum vitamin K concentration after 26 and 52 weeks of intervention